ACTIONABILITY KNOWLEDGE REPOSITORY ACTIONABILITY CURATION INTERFACE
Update History
Condition: Li-Fraumeni Syndrome
Gene/Gene Panel: TP53
Context: Pediatric
Date
Status
Outcomes-Interventions
Notes
2024/03/24
Released
1.0.3
Morbidity and mortality from Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 8CB
System migration to fix the sem versioning
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TP53 0018875 LI-FRAUMENI SYNDROME; LFS
Moderate Actionability
Strong Actionability
2024/03/24
Released (Under revision)
Morbidity and mortality from Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 8CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TP53 0018875 LI-FRAUMENI SYNDROME; LFS
Moderate Actionability
Strong Actionability
2023/07/14
Released
Morbidity and mortality from Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 8CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TP53 0018875 LI-FRAUMENI SYNDROME; LFS
Moderate Actionability
Strong Actionability
2023/07/14
Released (Under revision)
1.0.1
Morbidity and mortality from Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 8CB
Internal system migration associated with MONDO name addition.
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TP53 0007903 LI-FRAUMENI SYNDROME; LFS
Moderate Actionability
Strong Actionability
2022/02/09
Released
1.0.1
Morbidity and mortality from Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 8CB
Internal system migration associated with MONDO name addition.
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TP53 0007903 LI-FRAUMENI SYNDROME; LFS
Moderate Actionability
Strong Actionability
2022/02/09
Released (Under revision)
1.0.0
Morbidity and mortality from Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 8CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TP53 0007903 LI-FRAUMENI SYNDROME; LFS
Moderate Actionability
Strong Actionability
2021/07/21
Released
1.0.0
Morbidity and mortality from Li Fraumeni syndrome-associated cancers (GroupA)
Cancer surveillance (GroupA) 9CB
Avoidance of radiotherapy (GroupA) 8CB
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
TP53 0007903 LI-FRAUMENI SYNDROME; LFS
Moderate Actionability
Strong Actionability
2020/02/18
In Preparation
N/A
We have begun assessment of the Pediatric context for this topic
¤ Powered by BCM's Genboree.